Search clinical trials for: Dimethyl Fumarate

Total 1897 results

Biogen

Completed

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (PROTEC)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Czechia, Hungary, Austria, Belgium, Canada, Portugal, Slovakia, Slovenia
Central Hospital, Nancy, France

Completed

Multiple Sclerosis: Chi3L1 and Treatment Efficacy

Multiple Sclerosis
Banner Life Sciences LLC

Completed

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

Multiple Sclerosis

United States
Biogen

Completed

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

Multiple Sclerosis

United States
Biogen

Completed

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Belgium, Turkey, Bulgaria, United States, Czechia, Germany, Kuwait, Latvia, Lebanon
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...
Patient-Centered Outcomes Research Institute; Universita degli Studi di Genova

Terminated

Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis (PRAG-MS)

Relapsing Remitting Multiple Sclerosis

Italy
Michael Choi
The Leukemia and Lymphoma Society

Terminated

Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
AbbVie

Completed

A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Psoriasis

Germany
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Gliosarcoma | Adult Brain Glioblastoma

United States
Biogen

Completed

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Bulgaria, Belgium, Poland, Lithuania, Kuwait, Turkey
Fondation Ophtalmologique Adolphe de Rothschild

Terminated

Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate (SURV-SEP)

Multiple Sclerosis, Relapsing-Remitting

France
Biogen

Completed

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Korea, Republic of, Taiwan, Czechia, Japan, Poland
University Hospital Muenster
Biogen

Completed

Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Oregon Health and Science University
Biogen

Terminated

Tecfidera and MRI for Brain Energy in MS

Multiple Sclerosis

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

Relapsing-Remitting Multiple Sclerosis

United States
Multiple Sclerosis Center of Northeastern New York
Icahn School of Medicine at Mount Sinai; Biogen

Unknown

Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients

Multiple Sclerosis

United States
IMS HEALTH GmbH & Co. OHG
EMD Serono

Completed

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® (PROTRACT)

Relapsing-remitting Multiple Sclerosis

United States, Canada
Biogen

Completed

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

Relapsing Remitting Multiple Sclerosis

Germany
Alexza Pharmaceuticals, Inc.

Completed

Staccato Prochlorperazine in Migraine (in Clinic)

Migraine Headache, With or Without Aura

United States
Biogen

Completed

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS (FOCUS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Turkey, United States, Latvia, Lebanon, Germany, Belgium, Bulgaria, Czechia, Kuwait
Skane University Hospital

Withdrawn

Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic Arthritis

Psoriatic Arthritis

Sweden
Biogen

Completed

Study of Utilization Patterns of Dimethyl Fumarate in Germany

Multiple Sclerosis

Germany
Biogen

Completed

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Relapsing Forms of Multiple Sclerosis

United States
University of Michigan

Completed

Dimethyl Fumarate for Obstructive Sleep Apnea

Obstructive Sleep Apnea | Sleep Apnea | OSA

United States
Biogen

Terminated

Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.

Multiple Sclerosis

United States
Biogen

Terminated

Tecfidera Slow-Titration Study (TITRATION)

Multiple Sclerosis

United States, Belgium, Czech Republic, Italy
Biogen

Completed

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 (StarTec)

Multiple Sclerosis, Relapsing-Remitting

Italy
Biogen

Terminated

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis (INSPIRE)

Multiple Sclerosis, Secondary Progressive

United States, Poland, Belgium, Slovakia, Czech Republic, Netherlands
Biogen

Completed

Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany (TOLERATE)

Relapsing-Remitting Multiple Sclerosis

Germany
Biogen

Completed

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (EFFECT)

Multiple Sclerosis

United States, Italy, Hungary, United Kingdom, Spain, France, Australia, Germany, Canada, Switzerland, Argentina, Czech Republic, Croatia
Rocky Mountain MS Research Group, LLC
Biogen

Terminated

Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation (IIT9)

Relapsing Remitting Multiple Sclerosis

United States
Multiple Sclerosis Center of Northeastern New York
Biogen

Completed

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

Multiple Sclerosis

United States
Biogen

Completed

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis (EXPLORE)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (MANAGE)

Relapsing Forms of Multiple Sclerosis

United States
EMD Serono

Terminated

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (RESOunD)

Multiple Sclerosis

United States
Biogen

Completed

Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis (ASSURE)

Relapsing-Remitting Multiple Sclerosis

United Kingdom, Ireland
Almirall, S.A.

Completed

Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008 (LAS41008)

Psoriasis

United Kingdom
Virginia Simnad
Biogen

Unknown

Impact of Tecfidera on Gut Microbiota

Multiple Sclerosis

United States
University at Buffalo

Completed

Tecfidera Diffusion Tensor Imaging (DTI)

Multiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging
Yale University

Terminated

Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS

Multiple Sclerosis

United States
Biogen

Completed

Tecfidera Lymphocyte Chart Review (REALIZE)

Multiple Sclerosis

United States
Forward-Pharma GmbH

Withdrawn

Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Canada
Biogen

Completed

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS (RESPOND)

Relapsing Forms of Multiple Sclerosis

United States
Washington University School of Medicine
Biogen

Withdrawn

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Completed

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Healthy

United States
Biogen

Completed

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) (STRATEGY)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Withdrawn

Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
Biogen

Terminated

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting | Relapsing-Remitting Multiple Sclerosis

Canada
Brigham and Women's Hospital
EMD Serono

Withdrawn

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

Multiple Sclerosis

United States
Biogen
GB Pharma Services & Consulting s.r.l.

Withdrawn

Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis (PROMPT)

Relapsing Remitting Multiple Sclerosis

3

Subscribe